Beacon Pointe Advisors, LLC Viking Therapeutics, Inc. Transaction History
Beacon Pointe Advisors, LLC
- $9.37 Billion
- Q2 2025
A detailed history of Beacon Pointe Advisors, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Beacon Pointe Advisors, LLC holds 19,799 shares of VKTX stock, worth $750,778. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,799
Previous 33,079
40.15%
Holding current value
$750,778
Previous $798,000
34.34%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VKTX
# of Institutions
452Shares Held
67.9MCall Options Held
7.72MPut Options Held
3.25M-
Vanguard Group Inc Valley Forge, PA10.2MShares$385 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$229 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$143 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$123 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$119 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.91B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...